Anticancer Therapies – News and Features

In a clinical trial, a new drug prevented cancer growth in terminally ill patients, with 70% of those who received the medicine becoming stable after six weeks.

New research has found that physical activity can prevent, and not just delay, cancer recurrence in patients previously treated for colon cancer.

New data suggests immunotherapies may activate lymph nodes to produce tumor-fighting T cells.

By using nanotechnology to repair the pumping action of lymphatic vessels, Georgia Institute of Technology researchers have developed a unique approach to treating lymphedema.

Researchers have developed and used an upgraded tumor model that mimics bone to find that the body’s immune response can make tumor cells more resistant to chemotherapy.

In a new study, scientists show the commanding role of a specialized group of proteins in the nuclei of our cells, called mSWI/SNF (or BAF) complexes, both in activating T cells to attack cancer and triggering exhaustion.

A new study identifies a set of biomarkers that could help clinicians to predict whether pancreatic cysts will remain benign or develop into cancer.

A new study reveals the mechanisms responsible for the development of tumor resistance to a new drug, the first approved inhibitor against the KRAS oncogene.

A targeted therapy that combines two different drugs has been shown to be effective at reducing the size and number of non-small cell lung cancer tumors in mice.

The mechanism behind how tyrosine kinase inhibitors – a class of cancer drug – cause serious inflammatory side effects has been revealed by a new study.